Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.43 |
| ▸ | TFEB | P19484 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416380 | 0.89 | AR (0.49) | ALOX5PTGS1PTGS2SMN1; SMN2NFE2L2 | |
| SCHEMBL5414749 | 0.89 | LY96 (0.44) | ABCB1ALOX5PTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL5409655 | 0.89 | NPC1 (0.48) | ABCB1ALOX5PTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL5412818 | 0.84 | NFE2L2 (0.41) | SMN1; SMN2NFE2L2PTGES2 | |
| SCHEMBL27717896 | 0.84 | NFE2L2 (0.41) | SMN1; SMN2NFE2L2PTGES2 | |
| SCHEMBL27717766 | 0.83 | CYP1A1 (0.41) | SMN1; SMN2NFE2L2KDM4E | |
| SCHEMBL5411577 | 0.83 | CYP1A1 (0.41) | SMN1; SMN2NFE2L2KDM4E | |
| SCHEMBL4618136 | 0.82 | NFE2L2 (0.48) | SMN1; SMN2NFE2L2TFEBNR1H4KDM4E | |
| SCHEMBL5416929 | 0.81 | PTGES2 (0.48) | NFE2L2TFEBNR1H4KDM4EPTGES2 | |
| SCHEMBL5409216 | 0.80 | AR (0.49) | NFE2L2TFEBNR1H4KDM4EPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | ABCB1 90/4885ALOX5 1529/4885PTGS1 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.